214193-13-2 Usage
Uses
Used in Pharmaceutical Synthesis:
(1S,3S,5S)-2-AZABICYCLO[3.1.0]HEXANE-3-CARBOXYLIC ACID is used as a key building block for the synthesis of various pharmaceuticals and related compounds. Its unique bicyclic structure containing a nitrogen atom and chiral centers allows for the development of new drugs with specific therapeutic properties.
Used in Organic Synthesis:
(1S,3S,5S)-2-AZABICYCLO[3.1.0]HEXANE-3-CARBOXYLIC ACID is used as an intermediate in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications. Its versatility and unique structure make it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
(1S,3S,5S)-2-AZABICYCLO[3.1.0]HEXANE-3-CARBOXYLIC ACID is used as a starting material in medicinal chemistry for the development of new drugs and therapeutic agents. Its unique properties and structure contribute to the discovery and design of innovative pharmaceuticals with potential applications in various medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 214193-13-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,1,9 and 3 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 214193-13:
(8*2)+(7*1)+(6*4)+(5*1)+(4*9)+(3*3)+(2*1)+(1*3)=102
102 % 10 = 2
So 214193-13-2 is a valid CAS Registry Number.
214193-13-2Relevant academic research and scientific papers
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 71, (2015/02/25)
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: (structurally represented), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Probing the importance of spacial and conformational domains in captopril analogs for angiotensin converting enzyme activity
Hanessian, Stephen,Reinhold, Ulrich,Saulnier, Michel,Claridge, Stephen
, p. 2123 - 2128 (2007/10/03)
A new synthesis of 4,5-methano-L-prolines and the enzymatic activity of the corresponding N-(3-mercapto-2-R-methyl-propionyl) analogs as inhibitors of angiotensin converting enzyme are described.
